Check Claims Before You Publish

Critical appraisal — strengths, limitations, and blindspots

• Strengths (method): large panel sample (11,157 firm-year obs), use of fixed effects, mediation testing, and robustness checks increase internal consistency and lend moderate credibility to reported associations (Strengths: fixed effects, mediation, robustness).
• Limitations and potential biases: measurement error in DT (text-derived keyword index) can bias coefficients; endogeneity concerns (reverse causality or omitted variables) are acknowledged but not fully addressed via causal identification (e.g., IV, diff-in-diff); restricted to Chinese listed firms using CSMAR (paywalled), limiting external generalizability and reproducibility (Limitations listed by authors).
• Interpretation caution: reported associations are moderate in magnitude; the log-transformation of patent counts compresses large differences, so coefficient interpretation is percent-like but not directly causal without stronger identification (DV construction and interpretation).

Author-level evidence & gaps

Open bibliographic snapshots show multiple distinct researchers named "Yaxuan Zhou" (several OpenAlex identities with small publication counts). The dataset you supplied contains one concrete paper (2024 DT→GI) with structured metadata; beyond that, author-level metrics (total works, h-index) for this specific Yaxuan Zhou are not available in the supplied evidence. Because many scholars share the same name, bibliometric attribution requires disambiguation (ORCiD, institutional affiliation) which is absent here, so any strong claims about the author's career-level citation impact would be speculative without further disambiguating data.

What we can say from available evidence: the 2024 paper follows reasonably-standard empirical economics practice but is an applied corporate-level econometrics paper rather than a biological science contribution; therefore treat any biological-science competence claims about the named author as unsupported by the present evidence.

Conclusion & recommended next steps

1. Current evidence supports that the author (as credited on the 2024 paper) is capable of running large-sample panel regressions, mediation analysis, and robustness checks, but causal claims remain limited by endogeneity and measurement risks (Method competence and limits).
2. To strengthen an author-level scientific assessment we need: ORCiD, institutional affiliation, a complete publication list, independent citation metrics (Scopus/WoS/OpenAlex with disambiguation), and access to replication files/data or code; without these the author-level review must remain provisional.